Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | KCNJ11 | Q14654 | 3/20 | 0.44 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.43 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.43 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5543551 | 0.89 | KCNJ11 (0.49) | KCNJ11ABCC9ABCC8KCNJ8L3MBTL1 | |
| SCHEMBL1430230 | 0.83 | KMT2A (0.55) | HDAC1SMN1; SMN2KMT2AALDH1A1CYP1A2 | |
| SCHEMBL23322563 | 0.83 | PTGS2 (0.49) | PTGS2KMT2AALDH1A1 | |
| SCHEMBL20560736 | 0.83 | PTGS2 (0.49) | PTGS2L3MBTL1KMT2AALDH1A1 | |
| SCHEMBL5022119 | 0.83 | L3MBTL1 (0.53) | PTGS2KCNJ11ABCC9ABCC8KCNJ8 | |
| SCHEMBL10897021 | 0.83 | RIPK1 (0.51) | KCNJ11ABCC9ABCC8KCNJ8L3MBTL1 | |
| SCHEMBL15625386 | 0.82 | ALDH1A1 (0.49) | PTGS2KCNJ11SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL11856156 | 0.81 | KCNJ11 (0.49) | KCNJ11ABCC9ABCC8KCNJ8L3MBTL1 | |
| SCHEMBL28513817 | 0.79 | PTGS2 (0.44) | PTGS2L3MBTL1SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL9474094 | 0.79 | KCNJ11 (0.42) | KCNJ11ABCC9ABCC8KCNJ8L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638014-B1 | N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF ROR-GAMMA ACTIVITY AND THE TREATMENT OF DISEASES | LYCERA CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| US-9512111-B2 | N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease | LYCERA CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| US-20140088094-A1 | N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME CORP. (US) | 2014-03-27 | — | — | US | disclosed |
| WO-2012064744-A2 | TETRAHYDROQUINOLINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORϒ ACTIVITY AND THE TREATMENT OF DISEASE | LYCERA CORPORATION (US) | 2012-05-18 | — | — | WO | disclosed |
| EP-0470669-B1 | Preparation of fluorophenols, fluorohalophenols, N-acylfluoroanilines, and N-acylfluorohaloanilines | DOWELANCO (US) | 1997-11-12 | — | — | EP | disclosed |
| US-5164502-A | Fluorinating agents | DOWELANCO (US) | 1992-11-17 | — | — | US | disclosed |
| EP-0470669-A2 | Preparation of fluorophenols, fluorohalophenols, N-acylfluoroanilines, and N-acylfluorohaloanilines | DOWELANCO (US) | 1992-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088094-A1 | N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORC, RORB, RORA | PTGS2 1241/4885HDAC1 458/4885KCNJ11 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.